LENZ Therapeutics (LENZ) Asset Writedowns and Impairment (2023 - 2025)
LENZ Therapeutics (LENZ) reported Asset Writedowns and Impairment of $82000.0 for Q2 2025, down 99.39% quarter-over-quarter from $13.3 million in Q4 2023.
LENZ Therapeutics (LENZ) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends
LENZ Therapeutics (LENZ) has 2 years of Asset Writedowns and Impairment data on file, last reported at $82000.0 in Q2 2025.
- Asset Writedowns and Impairment for Q2 2025 came in at $82000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $82000.0 (changed N/A YoY), and the FY2025 annual result was $82000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment declined to $82000.0 in Q2 2025 per LENZ's latest filing, from $13.3 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $13.3 million in Q4 2023 and troughed at $82000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | LENZ Therapeutics | 213.20 Mn | 213.20 Mn | 825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 82,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Dec 31, 2023 | 13.35 Mn |
| Dec 31, 2023 | 13.35 Mn |
| Sep 30, 2023 | 7.22 Mn |
| Sep 30, 2023 | 7.22 Mn |